Article ID Journal Published Year Pages File Type
8447680 European Journal of Cancer 2011 6 Pages PDF
Abstract
ZOL administered with chemotherapy immediately and consistently reduced NTX levels for NPC patients with bone metastasis. Larger prospective randomised trial to confirm the efficacy of ZOL in NPC patients with bone metastases is pending.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases
Authors
, , , , , , , , , , ,